Figure 4.
Figure 4. Estimates of the probability of DFS, NRM, and relapse among patients with unfavorable cytogenetics who received a therapeutic dose of 131I-BC8 antibody, followed by BU/CY.

Estimates of the probability of DFS, NRM, and relapse among patients with unfavorable cytogenetics who received a therapeutic dose of 131I-BC8 antibody, followed by BU/CY.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal